Magnetic resonance imaging results from the first year of the ADVANCE study, a pivotal phase 3 trial of peginterferon β-1a in patients with relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2013
This article has no abstract
Epistemonikos ID: ec57e8cf86bd5fda271b81a7dd05388fa7574e9a
First added on: Apr 30, 2026